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Respiratory Syncytial Virus Infectivity in Cell Lines and Human
Tracheal-Bronchial Histocultures
Valeria Cagno,a Manuela Donalisio,a Andrea Civra,a Marco Volante,b Elena Veccelli,c Pasqua Oreste,c Marco Rusnati,d David Lemboa
Department of Clinical and Biological Sciences, University of Turin, Turin, Italya; Department of Oncology, University of Turin, Turin, Italyb; Glycores 2000 Srl, Milan, Italyc;
Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italyd
Respiratory syncytial virus (RSV) exploits cell surface heparan sulfate proteoglycans (HSPGs) as attachment receptors. The in-
teraction between RSV and HSPGs thus presents an attractive target for the development of novel inhibitors of RSV infection. In
this study, selective chemical modification of the Escherichia coli K5 capsular polysaccharide was used to generate a collection of
sulfated K5 derivatives with a backbone structure that mimics the heparin/heparan sulfate biosynthetic precursor. The screening
of a series of N-sulfated (K5-NS), O-sulfated (K5-OS), and N,O-sulfated (K5-N,OS) derivatives with different degrees of sulfation
revealed the highly sulfated K5 derivatives K5-N,OS(H) and K5-OS(H) to be inhibitors of RSV. Their 50% inhibitory concentra-
tions were between 1.07 nM and 3.81 nM in two different cell lines, and no evidence of cytotoxicity was observed. Inhibition of
RSV infection was maintained in binding and attachment assays but not in preattachment assays. Moreover, antiviral activity
was also evident when the K5 derivatives were added postinfection, both in cell-to-cell spread and viral yield reduction assays.
Finally, both K5-N,OS(H) and K5-OS(H) prevented RSV infection in human-derived tracheal/bronchial epithelial cells cultured
to form a pseudostratified, highly differentiated model of the epithelial tissue of the human respiratory tract. Together, these
features put K5-N,OS(H) and K5-OS(H) forward as attractive candidates for further development as RSV inhibitors.
Human respiratory syncytial virus (RSV) is an enveloped sin-gle-stranded negative-sense RNA virus belonging to the ge-
nus Pneumovirus of the family Paramyxoviridae (1). It is the lead-
ing cause of bronchiolitis and pneumonia in infants and young
childrenworldwide.More than half of all children are seropositive
for RSVby 1 year of age, and almost all children have been infected
by 2 years of age (2). Moreover, RSV is a pathogen of considerable
importance in immunocompromised adults and the elderly, par-
ticularly in those with chronic obstructive pulmonary disease (3).
In the United States alone, RSV is estimated to cause 120,000
hospitalizations each year and as many as 200 to 500 deaths in
infants/young children, while around 160,000 fatalities occur an-
nually worldwide (2, 4, 5). The economic burden related to RSV
infection is approximately $500million in theUnited States alone,
without taking outpatient care into account (6, 7).
Currently, the treatment of RSV infections ismainly symptom-
atic (8), and the development of a preventive vaccine is hampered
by difficulties in eliciting long-lasting protective immunity (9).
Antiviral therapy is limited to ribavirin, a nonspecific antiviral
drug that interferes with viral transcription; however, the nonneg-
ligible side effects of ribavirin and the recent recommendation of
the American Academy of Pediatrics not to routinely use this drug
in children with bronchiolitis (10) call for the development of
more selective and safe therapeutics for the treatment of RSV in-
fection (11, 12). For immunoprophylaxis, a monoclonal human-
ized antibody, palivizumab, is available, but it is administered only
to high risk premature newborns due to its high cost (13, 14).
Another antibody, named motavizumab (an affinity-matured
variant of palivizumab), was not provided with FDA approval due
to safety concerns (15). Thus, in view of the continual rise world-
wide in the morbidity and mortality of infants, the immunocom-
promised (in particular AIDS patients), and elderly individuals
resulting fromRSV infection (16, 17) and bearing inmind that no
antiviral drug exists to combat this pathogen, RSV constitutes an
important target for the development of new antiviral molecules.
The binding of RSV to cultured cells has been characterized at
the molecular level: it involves an initial interaction between the
positively charged basic amino acids presentwithin the linear hep-
arin-binding domain (HBD) (18) of the viral envelope proteins G
andF (19, 20) and the negatively charged sulfated/carboxyl groups
of the cell surface heparan sulfate proteoglycans (HSPGs). RSV
attachment to HSPGs is followed by a second interaction with
nucleolin, a cellular protein which is involved in attachment and
entry of several viruses, including human parainfluenza virus type
3, Crimean-Congo hemorrhagic fever virus, Japanese encephalitis
virus, and HIV (20, 21, 22, 23, 24, 25). Consequently, the interac-
tion between the envelope glycoproteins of RSV and cellular
HSPGs presents an attractive target for novel anti-RSV therapies.
HSPGs are associated with the cell surface; they consist of a
protein core and glycosaminoglycan (GAG) side chains of un-
branched sulfated polysaccharides, known as heparan sulfates
(HS), which are structurally related to heparin. Heparin and HS
consist of a sequence of glucuronic (GlcA) or iduronic acid (IdoA)
residues that are 1¡4 linked to a glucosamine (GlcN) molecule
that can beN-sulfated orN-acetylated. The disaccharide sequence
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can also be O-sulfated in different positions: positions 3 and 6 on
GlcN and position 2 on uronic acid. HS show high structural
heterogeneity along their chains, with specific regions responsible
for binding to different ligands.
In respect to HS, heparin is endowed with a high degree of
sulfation and amore homogeneous disposition of sulfated groups
along its saccharidic chain (26), and consequently, it usually binds
to cognate ligands (both viral and eukaryotic) with a higher affin-
ity thanHS, resulting in the strongest HSPG-antagonist activity in
competition experiments (27, 28, 29, 30). This identifies heparin
as an ideal reference compound in studies aimed at the identifica-
tion of polyanionic HSPG antagonist compounds.
Besides the case of RSV, HSPGs have also been demonstrated
to act as attachment receptors for human immunodeficiency virus
(HIV) (31), herpes simplex virus (HSV) (32), human papilloma-
virus (HPV) (33), human cytomegalovirus (HCMV) (34), dengue
virus (35), and filoviruses (36); accordingly, several anti-HSPG
strategies have been attempted for all of these viruses (29, 37, 38,
39, 40). Despite that fact that this huge amount of in vitro exper-
imentation initially provided promising results, few polyanionic,
heparin-like compounds progressed to clinical trial for different
viral diseases (41, 42, 43). These compounds were safe and well
tolerated in phase I and II studies but were devoid of any impor-
tant clinical benefit in phase III study. This failure of clinical trials
of earlier polyanionic antiviral compounds calls for the design of
newer compounds endowed with more controlled structures and
biological properties.
A peculiar class of compounds, namely, the sulfated derivatives
of capsular K5 polysaccharide from Escherichia coli, has emerged
as a promising biotechnological candidate agent for the develop-
ment of novel antiviral drugs (44). In brief, the capsular K5 poly-
saccharide from Escherichia coli has the same structure as the hep-
arin precursor N-acetyl heparosan. The chemical sulfation of K5
in various N and/or O positions along the polysaccharide results
in the synthesis of K5 derivatives with different degrees of sulfa-
tion and charge distribution that are endowed with specific bind-
ing capacities and biological properties. These semisynthetic
GAGs are devoid of the well-known anticoagulant activity that
prevents the use of heparin and other sulfated polysaccharides as
antivirals (26) and thus present a promising starting point for the
development of new antiviral formulations.
In effect, K5 sulfated derivatives have been demonstrated to be
endowed with inhibitory activity against different viruses, includ-
ing herpes simplex virus (HSV) (38), human papilloma virus
(HPV) (39), cytomegalovirus (CMV) (40), dengue virus (29), and
HIV (37). Regarding this last virus, K5 polysaccharides have been
demonstrated to classically act as antimicrobial agents, likely
binding to the basic gp120 protein but also binding to and neu-
tralizing otherHIV proteins released by infected cells (i.e., Tat and
p17) that contribute to HIV dissemination and to the onset of
AIDS-associated infections (30, 45). Taken together, these data
point to K5 sulfated derivatives as an interesting class of antiviral
compounds endowed with amultitarget activity that can be expli-
cated at different levels (i.e., against different viruses but also
aimed at different proteins of a given virus) (44). Relevant to this
point, a tight relationship exists between HIV, HSV, and HPV
infection, suggesting the possibility of generating K5-based drugs
with a multitarget mechanism of action that can control and/or
prevent HIV, HPV, and HSV infection simultaneously (44). In-
terestingly, a positive correlation has also been described for RSV
and HIV infections (46).
The aim of the present work was to investigate whether the
antiviral potential of K5 derivatives also extends to the respiratory
virus RSV. To this purpose, a panel of N-sulfated (K5-NS), O-sul-
fated (K5-OS), and N,O-sulfated (K5-N,OS) derivatives was
screened to identify compounds with RSV inhibitory activity; an-
tiviral potency and themode-of-action of the best-hit compounds
were also investigated. Highly sulfated (H) K5 derivatives K5-
N,OS(H) and K5-OS(H) emerged as nontoxic inhibitors of RSV
infectivity in both cell culture and an in vitro tissue model of hu-
man tracheal/bronchial epithelium.
MATERIALS AND METHODS
Heparin andK5polysaccharide derivatives.Unmodified unfractionated
beef mucosal heparin was obtained from Laboratori Derivati Organici,
Milan, Italy. K5 polysaccharide derivatives were obtained by N-deacety-
lation/N-sulfation and/or O-sulfation of a single batch of K5 polysaccha-
ride as previously described (47). The N-deacetylation/N-sulfation of K5
polysaccharide is performed in one step and has been scaled to a 10-g
amount. The average yield of compound of the N-deacetylation/N-sulfa-
tion is about 80%. The degree of N-sulfation is determined by 1H nuclear
magnetic resonance (1H-NMR) at 500 MHz, and no signal of residual
N-acetylation is detectable. The sulfate-to-carboxyl ratio of the final prod-
ucts is measured according to themethod of Casu et al. (48). The antiviral
results have been reproduced with two different batches of compounds.
The main chemical features of these GAGs are shown in Table 1.
Cells and viruses.The epithelial cell linesHEp-2 (ATCCCCL-23) and
A549 (ATCC CCL-185) were grown as monolayers in Eagle’s minimal
essential medium (MEM) (Gibco/BRL, Gaithersburg, MD) supple-
mented with heat-inactivated 10% fetal calf serum (FCS) (Gibco/BRL).
RSV strain A2 (ATCCVR-1540) was propagated in HEp-2 cells by infect-
ing a freshly prepared confluentmonolayer grown inMEMsupplemented
with 2% of FCS. When the cytopathic effect involved the whole mono-
layer, the infected cell suspension was collected and the viral supernatant
was clarified. The virus stocks were aliquoted and stored at 80°C. The
infectivity of virus stocks was determined on HEp-2 cell monolayers by
standard plaque assay. The cell lines and the RSV were obtained from the
American Type Culture Collection (Manassas, VA, USA).
Cell viability assay. Cells (A549 and HEp-2) were seeded at a density
of 5  104/well in 96-well plates and treated the next day with serially
diluted GAGs to generate dose-response curves. After 72 h of incubation,
cell viability was determined using the CellTiter 96 proliferation assay kit
(Promega, Madison, WI, USA), according to the manufacturer’s instruc-
tions. Absorbances were measured using a microplate reader (model 680;
Bio-Rad) at 490 nm. Fifty percent cytotoxic concentration (CC50) values
and 95% confidence intervals (CIs) were determined using Prism soft-
ware (GraphPad Software, San Diego, CA).
Virus inactivation assay. Approximately 104 PFU of RSV and 3.6
g/ml of each GAG (corresponding to 240 nM K5-N,OS(H), 191 nM
K5-OS(H), and 263 nMheparin)were added toMEMandmixed in a total
TABLE 1 Molecular weights and degrees of sulfation of the GAGs used
in this work
Compound Mol wt SO3
/COO ratio
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volume of 100 l. Virus-GAGmixtures were incubated for 2 h at 37°C or
4°C and serially diluted to the noninhibitory concentration of each test
compound, and the residual viral infectivity was determined by the viral
plaque assay.
Binding assay. Each GAG (10 M) was added to an aliquot of RSV
(5 104 PFU) and administered directly to HEp-2 or A549 cell monolay-
ers in MEM supplemented with 2% FCS, incubated for 2 h at 4°C, and
washed three times to remove unbound virus. Cells were then fixed with
4% paraformaldehyde, air dried, and blocked with 5% bovine serum al-
bumin (BSA) in phosphate-buffered saline(PBS)-Tween. Bound virus
was detected using RSV monoclonal antibody (Ab35958; Abcam, Cam-
bridge, United Kingdom) (diluted 1:400), incubated for 1 h at room tem-
perature, washed three times with PBS-Tween, and incubated for 2 h at
37°C with goat anti-mouse IgG conjugated to horseradish peroxidase
(HRP) (1:1,000). At the end of incubation, plates were washed three times
with PBS-Tween before adding the ABTS substrate [2,2=-azinobis(3-eth-
ylbenzthiazolinesulfonic acid)] (Thermo Scientific, Rockford, IL) and
reading the absorbance at 405 nm. Percent inhibition of virus binding was
determined by comparing the absorbancemeasured in the presence of the
compound to that measured in untreated cultures.
Viral plaque assay. To evaluate the capacity to inhibit RSV infection,
GAGs were serially diluted to generate dose-response curves and added to
RSV (multiplicity of infection [MOI], 0.01 PFU/cell). After 1 h of incuba-
tion at 4°C, the mixture was added to cells grown as monolayers in a
96-well plate at a density of 5 104/well. After 3 h of incubation at 37°C,
monolayers were washed and overlaid with 1.2% methylcellulose me-
dium. Three days postinfection, cells were fixed with cold methanol and
acetone for 1min and subjected toRSV-specific immunostaining using an
RSV monoclonal antibody (Ab35958; Abcam, Cambridge, United King-
dom) and theUltraTechHRP streptavidin-biotin detection system (Beck-
man Coulter, Marseille, France). Immunostained plaques were counted,
and the percent inhibition of virus infectivity was determined by compar-
ing the number of plaques in compound-treated wells with the number in
untreated control wells. Fifty percent inhibitory concentration (IC50) val-
ues and 95% CIs were determined using Prism software. All data were
generated from duplicate wells in at least three independent experiments.
To characterize the mechanism of the antiviral action of the K5 deriv-
atives, the viral plaque assay was repeated, incorporating the following
modifications.
Preattachment assay. HEp-2 and A549 cell monolayers in 96-well
plates were incubatedwith increasing concentrations of the various GAGs
for 2 h at 37°C. After removal of the compound and two gentle washes,
cells were infected with RSV (MOI, 0.01 PFU/cell) in the absence of com-
pounds for 3 h at 37°C. Cells were then overlaidwith 1.2%methylcellulose
medium, incubated for 72 h at 37°C, and successively fixed and immuno-
stained as described above. Plaques were then counted.
Attachment assay. Serial dilutions of the various GAGs were preincu-
bated with RSV (MOI, 0.05 PFU/cell) for 1 h at 4°C, added to cooled
HEp-2 and A549 cells in 96-well plates, and incubated for 2 h at 4°C to
ensure viral attachment but not entry. After two gentle washes, cells were
overlaid with 1.2%methylcellulose medium, shifted to 37°C for 72 h, and
successively fixed and immunostained as described above. Plaques were
then counted.
Postattachment assay measuring viral yield.HEp-2 cell monolayers
in 24-well plates were infected with RSV (MOI, 0.005 PFU/cell) in MEM
supplemented with 2% FCS for 3 h at 37°C and then subjected to two
gentle washes to remove unbound virus. Increasing concentrations of the
various GAGs in MEM supplemented with 2% FCS were then added to
cultures after washout of the viral inoculum or after 1, 2, 3, or 24 h.
Incubation continued until the cytopathic effect involved the whole
monolayer in the untreated wells. The infected cell suspensions were col-
lected, and the supernatants were clarified. RSV infectivity was deter-
mined on A549 cell monolayers by standard plaque assay. Titrations were
carried out at dilutions at which compounds were no longer active to
exclude the possibility that a carryover of tested polysaccharides into the
titration culture would block virus attachment.
Percent inhibition was determined by comparing the viral titer mea-
sured in the presence of the compounds to that measured in untreated
wells.
Syncytium formation assay. The abilities of the various GAGs to
block RSV cell-to-cell spread were evaluated using a previously described
method (49) with minor modifications. Cell monolayers in 96-well plates
were infectedwithRSV (MOI, 0.01 PFU/cell) inMEMsupplementedwith
2% FCS for 3 h at 37°C and then subjected to two gentle washes to remove
unbound virus. Following inoculum washout, increasing concentrations
of each GAG in 1.2% methylcellulose medium were then added to cul-
tures. Incubation continued for 72 h postinfection at 37°C; cells were then
fixed and immunostained. The immunostained syncytia were visualized
using a Leica inverted microscope equipped with a Bresser MikroCam
microscope camera and MikroCamLab software (Rhede, Germany). Im-
ageJ software was used to quantify plaque sizes. Untreated RSV-infected
monolayers were used as the control.
Rotavirus infectivity assay. Rotavirus infectivity assays were per-
formed as previously described (50) with some modifications. Confluent
MA104 cell monolayers in a 96-well plate were washed twice with MEM
and then infected with human rotavirus strainWa (ATCCVR-2018) at an
MOI of 0.02 PFU/cell for 1 h at 37°C in the presence or absence of each test
GAG. Virus was preactivated with 5 g of porcine trypsin (Sigma)/ml for
30 min at 37°C. After the adsorption period, the virus inoculum was
removed, cells were washed withMEM, and the cultures weremaintained
at 37°C for 16 h in medium with trypsin at 0.5 g/ml. The infected cells
were fixed and immunostained using an UltraTech HRP streptavidin-
biotin detection system (Beckman Coulter).
EpiAirway tissues. EpiAirway tissues, cultured on collagen supports
under air-liquid interface conditions, were obtained from MatTek Corp.
(Ashland, MA, USA). These tissues consisted of normal human-derived
tracheal/bronchial epithelial cells that are highly differentiated (i.e., con-
tain cilia, tight junctions, sodium and chloride channels, etc.) and retain
properties of normal respiratory tract epithelial tissue (i.e., actively secrete
mucus, electrogenicity, etc.). Upon delivery, the EpiAirway tissue inserts
were processed according to the supplier’s protocol. Briefly, each tissue
insert was transferred to a well in a 6-well plate prefilled with 900 l
prewarmed serum-freemedium (Air-100-MM;MatTek Corp.) and incu-
bated at 37°C in 5% CO2 overnight (16 to 18 h). EpiAirway tissues were
then used in the following three assays.
Cytotoxicity assay. The cytotoxicity of K5 derivatives on mucous
membranes was assessed using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-di-
phenyl-2H-tetrazolium bromide (MTT) ET50 tissue viability assay ac-
cording to the manufacturer’s instructions. K5 derivatives (10 M) were
applied to the cell culture insert on top of the EpiAirway tissue samples
and incubated for 1, 4, or 18 h at 37°C in duplicate. At the end of the
incubation, any liquid on top of the EpiAirway tissue was decanted, and
inserts were gently rinsed with PBS to remove any residual material. Tis-
sues were then processed according to the MTT kit protocol (MatTek
Corporation) and read using an enzyme-linked immunosorbent assay
(ELISA) plate reader at a wavelength of 570 nm. Tissues incubated with
assay medium were used as negative controls. The ET50 is the time re-
quired to reduce tissue viability to 50% and was determined using Prism
software (GraphPad Software, SanDiego, CA). According to the informa-
tion provided by the supplier, ET50 values of18 h indicate that a tested
compound is not irritating.
Antiviral assay. To assess the antiviral activity of K5 derivatives on
EpiAirway cultures, aliquots of 100l of medium containing 50,000 PFU
of RSV with or without K5 derivatives (10M)were preincubated for 1 h
at 4°C and then added to the apical surface of the tissues. After 3 h of
incubation at 37°C, the medium was removed, and the cultures were
washed apically with 100 l of medium and then fed each day via the
basolateral surface with 1 ml medium. To harvest the virus, 100 l me-
dium was added to the apical surface, and the tissues were allowed to
Cagno et al.
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equilibrate for 30 min at 37°C. The suspension was then collected and
stored at80°C until viral titers were determined by plaque assay in A549
cell monolayers as described above. Collection of virus was performed
sequentially from the same wells on each day postinfection.
Detection of RSV in EpiAirway tissue by immunohistochemistry.
RSV was detected immunohistochemically using a specific mouse mono-
clonal antibody against RSV (Ab35958; Abcam, Cambridge, United King-
dom). Briefly, EpiAirway tissue cultures exposed to RSV in the absence or
presence of K5 derivatives (10 M) were fixed in buffered formalin and
embedded (properly oriented) in paraffin togetherwith adherent collagen
membranes. Immunohistochemical sections were processed for antigen
retrieval in citrate buffer using a dedicated pressure cooker (1 cycle for 5
min at 125°C, followed by 10 s at 90°C) in parallel with sections stained
with conventional hematoxylin and eosin. Following incubation with the
primary antibody (1:500 dilution), the reaction product was visualized
using a biotin-free polymer-conjugated secondary antibody (Envision;
Dako, Glostrup, Denmark). In the presence of a positive reaction, the
antibody showed cytoplasmic and nuclear immunoreactivity, mostly rec-
ognizable in the cells of the superficial layers. Ten sections were analyzed
for each experimental condition.
Statistical analysis. Inhibition of infectivity and formation of syncytia
in the presence and absence of the putative antiviral compounds were
compared by analysis of variance (ANOVA) followed by a Bonferroni
posttest, if P values showed significant differences, using the GraphPad
Prism 5.00 program (GraphPad Software). Results are expressed as
meansCI or standard errors of themeans (SEM) or standard deviations
(SD), as appropriate.
RESULTS
Screening of derivatives of E. coli K5 polysaccharide for RSV
antiviral activity. Knowing that heparin is structurally related to
HSPG and prevents RSV adsorption (19), we exploited the viral
plaque assay to screen a panel of E. coli K5 polysaccharide deriva-
tives, which have structures similar to those of heparin and HSPG
(26). As reported in Table 2, all GAGs, except unmodified K5,
showed a half-maximal inhibitory concentration (IC50) in the
nanomolar range. To exclude the possibility that the antiviral ac-
tivity of K5 derivatives might be due to cytotoxicity, the GAGs
were evaluated by MTT assays with uninfected HEp-2 and A549
cells. As reported in Table 2, none of the GAGs tested exhibited
toxic effects in the range of the examined concentrations, hence
the nondeterminable 50% cytotoxic concentrations (CC50) and
very favorable selectivity indexes (SI) for each active compound.
K5-N,OS(H) and K5-OS(H) were endowed with the highest anti-
viral activities and were therefore selected for further investiga-
tion. Thus, the effect of K5-N,OS(H) and K5-OS(H) on cell via-
bility was investigated with HEp-2 and A549 cells at higher doses
than those reported in Table 2 (i.e., up to 200 M) in order to
determine the CC50 values. As shown in Fig. S1 in the supplemen-
tal material, K5-N,OS(H) and K5-OS(H) exerted a moderate
dose-dependent reduction in cell viability only inHEp-2 cells at 50
M, 100M, and 200M, which did not allow the calculation of
CC50 values
K5 derivatives do not inactivate RSV particles. Since certain
sulfated polysaccharides have been shown to exhibit direct viru-
cidal activity (51), the K5 derivatives used in the present study
were first subjected to a virus inactivation assay in our pursuit to
understand their mechanism(s) of antiviral action. As shown in
Fig. 1, the virus titers of samples treated with K5-N,OS(H), K5-
OS(H), or heparin did not significantly differ from those deter-
mined in untreated samples (P 0.05), indicating that the twoK5
derivatives do not exert their antiviral activity via the direct inac-
tivation of RSV particles.
K5 derivatives do not affect cell susceptibility to RSV infec-
tion. Some antiviral compounds are known to lower cell suscep-
tibility to viral infection by downregulating or directly masking
virus receptors. In particular, we recently demonstrated that the
compound SB-105A10 exerts its anti-RSV activity by masking
HSPGs on the cell surface (49). To investigate whether the K5
derivatives affect cell susceptibility to RSV infection, preattach-
ment assays were performed as described above. To this end,
HEp-2 and A549 cells were preincubated for 2 h with different
concentrations of K5-N,OS(H) or K5-OS(H) or with heparin as a
control. After incubation, cells were washed to remove unbound
GAGs from the medium and infected with RSV. As shown in Fig.
2, under these experimental conditions, K5 derivatives and hepa-
rin do not exert any antiviral activity. This indicates that K5 de-
rivatives do not affect cell susceptibility to RSV infection.
K5 derivatives block RSV binding to host cells. The antiviral
activities of many sulfated polysaccharides correspond to their
capacity to bind to and sequester the virus in the extracellular
environment, thus hampering its attachment to the target cell
(51). This possible mechanism was therefore investigated in rela-
tion to the K5 derivatives and RSV using the attachment assay
described above, the conditions of which allow for the attachment
of the virus to the cell surface but prevent its entry. As shown in
Fig. 3, under these experimental conditions, K5 derivatives and
heparin strongly inhibited RSV, with IC50s that are comparable to
those measured in the classical viral plaque assay (see Table 2),
suggesting that the antiviral activities of these GAGs depend on
their capacity to inhibit the attachment of the virus to the cell
surface.
To substantiate this interpretation, binding assays in which
we directly evaluated the amounts of virus particles bound to
the cells in the presence or absence of the active GAGs were
performed. Consistent with previous results, K5-N,OS(H), K5-
OS(H), and heparin significantly reduced (P  0.05) the
amount of bound virus on HEp-2 and A549 cells (Fig. 3C and
D, respectively), while unsulfated K5, which does not exhibit
any antiviral activity, did not.
Taken together, these results indicate that the main mecha-
TABLE 2 Screening of K5 derivatives on A549 and HEp-2 cellsa
Cell
line Compound IC50(nM) 95% CI CC50 (nM) SI
A549 K5 600 NA 24,000 40
K5- NS 257.40 164.5–402.8 24,000 93.24
K5-N,OS(L) 36.81 23.3–58.2 24,000 651.99
K5-N,OS(H) 2.56 2.07–3.18 24,000 9,375
K5-OS(L) 25.42 15.2–42.5 24,000 944.14
K5-OS(H) 1.07 0.704–1.624 24,000 22,429.91
Heparin 3.52 2.08–5.96 24,000  6,818.18
HEp-2 K5 600 NA 24,000 40
K5-NS 340 240–500 24,000 70.59
K5-N,OS(L) 28.81 21.88–37.94 24,000 833.04
K5-N,OS(H) 3.71 3.36–4.12 24,000 6,469
K5-OS(L) 44.69 31.34–63.72 24,000 537.03
K5-OS(H) 2.20 1.76–2.74 24,000 246,857
Heparin 3.73 3.17–4.39 24,000 6,434.32
a IC50, 50% inhibitory concentration; 95% CI, 95% confidence interval; CC50, 50%
cytotoxic concentration; NA, not assessable. Values are means and CIs from three
separate determinations.
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nism of action of the K5 derivatives consists in their capacity to
hamper the virus’s interactionwith an entry receptor(s) expressed
on the surface of target cells.
K5 derivatives reduce viral yield for 24 h postinfection. To
evaluate whether the reduction of RSV attachment and infection
exerted by K5-N,OS(H) and K5-OS(H) is maintained in the long
term, thus leading in a decrease in viral progeny production, post-
attachment assays using virus yield were performed as described
above; this stringent test allows multiple cycles of viral replication
to occur beforemeasuring the production of infectious viruses. In
the first set of experiments, increasing concentrations of K5-
N,OS(H), K5-OS(H), and heparin were added immediately after
the removal of the viral inoculum in order to generate dose-re-
sponse curves and to determine the IC50s (Fig. 4A). Under these
experimental conditions, the two K5 derivatives strongly reduced
the RSV yield, with efficiencies that are similar to those measured
in the classic viral plaque assay and in the attachment assay for
K5-N,OS(H) and K5-OS(H), respectively. Interestingly, heparin
exerted only modest inhibitory activity. Of note, K5-N,OS(H),
K5-OS(H), and heparin were not cytotoxic even at the highest
concentration tested (7 M), as shown in Fig. S1 in the supple-
mental material.
In the second set of experiments, a single concentration of
K5-N,OS(H), K5-OS(H), or heparin was added 1 h, 2 h, 3 h, and
24 h after the removal of the virus inoculum. The results shown in
Fig. 4B demonstrate that reduction in viral yield is effective when
the compounds are added up to 24 h postinfection. Once again,
the inhibition profiles of K5-N,OS(H) and K5-OS(H) were better
than that of heparin.
Taken together, these data indicate that the K5 derivatives but
not heparin retain an antiviral activity for at least 24 h and are able
to exert their inhibitory action over virions produced directly by
the cell, thereby preventing further cell infection and viral yield
production.
K5 derivatives inhibit cell-to-cell spread of RSV and syncy-
tium formation. Massive viral production by infected cells trig-
gers cell-to-cell spread of RSV that in turn triggers the formation
of syncytia, the characteristic cytopathic effect of RSV; the forma-
tion of these large, multinucleated epithelial cells helps the infect-
ing virus avoid antibodies present in nasal secretions (52, 53). We
thus decided to investigate whether K5-N,OS(H), K5-OS(H), and
heparin were able to block the cell-to-cell transmission of RSV. To
this end, HEp-2 and A549 cells were infected with RSV in the
absence of any GAG and then treated with different concentra-
tions of K5-N,OS(H), K5-OS(H), or heparin after the removal
of the virus inoculum. Three days postinfection, the cell-to-cell
spread of RSV was evaluated by analyzing the size of the infec-
tion foci. As shown in Fig. 5A, all the compounds were able to
reduce the transmission of RSV in a dose-dependent manner. A
statistically significant reduction in syncytium dimension was
observed in both A549 and HEp-2 cells treated with doses of
K5-N,OS(H) ranging between 7 M and 777.8 nM, and with
doses of K5-OS(H) ranging between 7 M and 259.3 nM. In
contrast, a significant reduction in plaque size following treat-
ment with heparin was observed in HEp-2 cells only at a dose of
7 M (P  0.01).
K5 derivatives do not exhibit antiviral activity against rota-
virus. To date, a number of K5 derivatives that exhibit antiviral
activity against a panel of HSPGs-dependent viruses, including
HSV, HIV, and HPV (see the introduction), have been identified.
Moreover, work from our own group has revealed the HSPG-
binding dendrimer SB105A10 to be active against RSV infection
(49), and the present study identifies additional K5 derivatives
with capacities to block RSV infection. To provide further evi-
FIG 1 K5 derivatives are not active in a virus inactivation assay. RSV was incubated with 3.6 g/ml of K5-N,OS(H) (240 nM), K5-OS(H) (191 nM), or heparin
(263 nM) for 2 h at 4°C or 37°C. The mixtures were then titrated on A549 cells at high dilutions at which the concentrations of compounds were not active. The
titers, expressed as PFU/ml, are means and SEM for triplicates.
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dence corroborating the hypothesis that the anti-RSV abilities of
these K5 derivatives depend specifically on their capacity to pre-
vent RSV from interactingwithHSPGs on the target cell, the com-
pounds were tested against human rotavirus, whose attachment
and entry depend on interaction with integrins and heat shock
proteins but not HSPG (54). Neither the K5 derivatives nor hep-
arin could prevent rotavirus infection inMA104 cells when tested
at doses up to 7 M (Fig. 6), strongly indicating that these com-
pounds are not active against viruses that do not bind to cell sur-
face HSPGs.
Antiviral activities ofK5derivatives in EpiAirway tissue.The
EpiAirway system consists of human derived tracheal/bron-
chial epithelial cells grown on a collagen-coated membrane to
form a highly differentiated organotypic model with many of
the features of respiratory mucosa, thus providing a useful in
vitro means of assessing respiratory virus infections. We as-
sessed the effect of K5-N,OS(H) and K5-OS(H) on RSV infec-
tion by measuring the titer of virus emerging from the apical
surface of tissues infected with mixtures containing 50,000
PFU of RSV in the presence or absence of 10 M K5-N,OS(H)
or K5-OS(H) preincubated for 1 h at 4°C prior to virus appli-
cation. At 72 h postinfection, the titer of virus in untreated
control tissues was 1.45  103 PFU/ml. In tissues treated with
K5-N,OS(H), the detected titer was 40 PFU/ml, whereas in the
samples treated with K5-OS(H), the virus titer was undetect-
able (Fig. 7). Thus, the compounds inhibited the viral titer by
97.3% and 100%, respectively. The same tissues were fixed im-
mediately after the virus harvest at 72 h postinfection and sub-
jected to immunohistochemistry using an RSV-specific mono-
clonal antibody. All the sections derived from the infected
tissue consistently showed the presence of cells expressing the
RSV antigen in the upper cellular layer (Fig. 8B). No RSV-
positive cells could be observed in sections from uninfected
tissue (Fig. 8A), demonstrating the specificity of the signal.
Furthermore, no RSV-positive cells could be identified in tis-
sues treated with K5-N,OS(H) (Fig. 8C) or K5-OS(H) (Fig.
8D), corroborating the virus titer results. To verify that the
antiviral action was not due to a cytotoxic effect, an MTT assay
was performed with tissues treated with 10 M (each) K5 de-
rivative for 1, 4, or 18 h at 37°C. The results shown in Table 3
FIG 2 Preattachment assay with HEp-2 and A549 cells. HEp-2 (A) or A549 (B) cells were pretreated with increasing concentrations of K5 derivatives or heparin
for 2 h at 37°C, washed, and infected. Three days postinfection, the cells were fixed and subjected to RSV-specific immunostaining, the plaques were counted, and
the percent infection was calculated by comparing treated and untreated wells. The results are means and SEM for triplicates.
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demonstrate that these K5 derivatives are not cytotoxic, and
the time required to reduce tissue viability to 50% (ET50) was
greater than 18 h.
DISCUSSION
To infect target cells successfully, RSV needs to bind to HSPGs
located on the cell membrane, and this interaction provides a tar-
get for the development of new anti-RSV compounds. Inhibition
of the RSV/HSPG interaction can be achieved by two distinct ap-
proaches: the first involves receptor masking, usually achieved by
means of polycationic compounds able to bind to the negatively
charged sulfate groups present on the GAG side chains of HSPGs,
and the second involves the use of polyanionic compounds that
bind to and antagonize the virus. We recently confirmed the fea-
sibility of the first approach by demonstrating that a highly posi-
tively charged dendrimer effectively binds to HSPGs, inhibiting
RSV infection (49). Accordingly, positively charged peptides de-
rived from the HBD of the RSV G protein also block virus infec-
tion (18). The feasibility of the second approach, on the other
hand, has been supported by the demonstration that heparin (19,
55) and other negatively charged polysaccharides, such as chon-
droitin sulfate (56) and dextran sulfate (57, 58), are able to bind
RSV, preventing its cell attachment and infection.
Due to their structural heterogeneity, heparin, heparan sulfate,
and other GAGs are able to bind to a wide range of molecules and
exert a number of biological activities that can interfere with one
another, leading to the risk of toxicity and undesired side effects.
The solution therefore lies in the production of tailor-made hep-
arin-like compounds endowed with specific antiviral activities;
however, this requires detailed knowledge of the molecular basis
of the heparin/HSPG interaction with viral envelope proteins. In
the case of RSV, we know that the glycoproteins G and F are
responsible for the heparin/HSPG interaction, and specific basic
amino acid sequences acting as HBDs have even been identified in
the each of these proteins (18, 19, 20). Nevertheless, little has been
done to date to characterize the structural features of heparin/
HSPGs that mediate their binding to RSV protein, although it is
very likely that the negatively charged sulfated groups of the GAG
chains are those involved in the interaction, as demonstrated for
almost all the other viral heparin-binding proteins (59).
The capsular K5 polysaccharide from Escherichia coli can be
chemically sulfated in selected positions, resulting in the synthesis
of completely N-sulfated compounds with different amounts of
O-sulfation in different positions or completely N-acetylated
molecules differing only in the position and degree of O-sulfation
(30). Due to these features, sulfated K5 derivatives have been use-
ful in the study of the structure-activity relationship of the inter-
actions of several viral proteins with heparin and used in the de-
sign of specific antiviral polysaccharides.
Here, we found that selected K5 sulfated derivatives exert a
strong anti-RSV effect. Experiments aimed at elucidating their
mechanism(s) of anti-RSV action indicate that the inhibitory ef-
FIG 3 Investigation of inhibitory mechanisms of the hit compounds. In the attachment assay, RSV and compounds were added to HEp-2 (A) or A549 (B) cells
for 2 h at 4°C. Cells were shifted to 37°C, and at 72 h postinfection, they were subjected to RSV-specific immunostaining, the plaques were counted, and the
percentage of infection was calculated by comparing treated to untreated wells. In the binding assay, the virus bound to HEp-2 (C) or A549 (D) was detected by
ELISA immediately after the removal of the virus inoculum. Each absorbance wasmock subtracted, and the percentage of infection was calculated by comparing
treated to untreated wells. The results are means and SEM from triplicates.
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fect is due mainly to the capacity of K5-N,OS(H) and K5-OS(H)
to interact with the virus particles, rather than with cell compo-
nents, and thereby prevent virus attachment to the cell surface.
Several lines of evidence support this. First, cells pretreated with
K5 derivatives remained susceptible to RSV infection, thus ex-
cluding the possibility that these compounds form stable interac-
tions with one or more cellular components, preventing their in-
teraction with viral glycoproteins. Second, the results of the
binding and attachment assays demonstrate that K5-N,OS(H)
and K5-OS(H) block the adsorption of RSV virions to the cell
surface with a potency similar to that of heparin, which has been
shown to prevent RSV infection by competing with cellular
HSPGs for binding to virion components (60, 61) Third, preincu-
bation of RSV virions with the active sulfated K5 derivatives did
not result in a loss of infectivity, suggesting that the antiviral ac-
tivity of the compounds does not rely on inactivation of a virion
component(s). A similar mechanism of action was previously ob-
served for heparin when it was tested against HSV-1 and RSV (49,
50) and when K5 derivatives were tested against HCMV (40).
Unsulfated K5 polysaccharide, unlike K5-N,OS(H) and K5-
OS(H), did not show any significant RSV antagonist activity, in-
dicating that the sulfate groups, rather than the backbone struc-
ture, mediate the interaction with RSV. Moreover, a good
correlation exists between the degree of sulfation of the GAGs
tested and their capacities to inhibit RSV infection (Fig. 9). How-
ever, this correlation is lost in the highly sulfatedGAGs (see the left
part of Fig. 9); thus, in addition to the degree of sulfation, the
position of the sulfate groups along the polysaccharide chain is
also important. Furthermore, complete sulfation of the N posi-
tions confers very limited RSV antagonist activity to K5-NS, while
FIG 4 Reduction of viral yield. (A) HEp-2 cells were infected and subsequently treated with different concentrations of compounds. When the cytopathic effect
involved the whole monolayer of untreated wells, supernatant were harvested and titrated. The results are means and SEM from triplicates. The table in panel A
shows the IC50 and 95% CI values for each compound tested. (B) The same procedure was followed, with a fixed dose of 10 g/ml added to infected cells at
different times postinfection, ranging from 0 h to 24 h. The results are means and SEM for triplicates. , P 0.05 in a 2-way ANOVA.
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sulfation of the O position confers an inhibitory capacity to K5-
OS(L) that is almost 10 times higher than that of K5-NS (Table 2)
despite a similar SO3
/COOH ratio (1 and 1.5, respectively)
(Table 1). Similarly, K5-OS(H) is endowed with an inhibitory
capacity that is 30 times higher than that of K5-N,OS(L) (Table 2)
despite their similar SO3
/COOH ratios (2.7 and 2.2, respec-
tively) (Table 1). Finally, the greater SO3
/COOH ratio of K5-
OS(H) than that of K5-NOS(H) (from 2.7 to 3.68) (Table 1) does
not confer any additional anti-RSV potency.
Taken together, these data suggest that O- rather than N-sul-
fated groupsmediate the binding of RSV toK5 polysaccharides. In
apparent contrast with our findings, Hallak and coworkers dem-
onstrated that N-sulfation of heparin is necessary for RSV infec-
tion (55). In this regard, it must be pointed out that heparin (but
FIG 5 Inhibition of RSV-induced syncytium formation by K5 derivatives and heparin. The images in panel A show representative syncytia in HEp-2 cells, with
horizontal bars corresponding to 20m. HEp-2 cells (B) or A549 cells (C) were infected with RSV in the absence of compounds. The inoculum was removed at
3 h postinfection, and cells were left untreated or incubated in the presence of the following concentrations of substances in 1.2%methylcellulosemedium: 7,000
nM, 2,333.3 nM, 777.8 nM, and 259.3 nM. Formation of syncytia was assessed 72 h after infection, by immunostaining. The histograms show the percentage of
plaque area of treated wells compared to that of untreated wells as a function of compound concentration. The pictures and histograms shown are representative
of many analyzed plaques, ranging from 15 to 25 per condition. , P 0.001; , P 0.01.
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notK5 derivatives) is epimerized and that the presence of iduronic
acid instead of glucuronic acid residues confers on heparin greater
flexibility (62) that in turn may allow a better presentation of the
N-sulfated groups to the RSV envelope proteins G and F. In ac-
cordancewith this hypothesis, when theRSV antagonist capacities
of the K5 derivatives are compared to that of heparin, it is evident
that their activities are enhanced by the presence of IdoA, since K5
N,OS(L) is much less active despite a similar sulfate-to-carboxyl
ratio (2.2 and 2.4). Thus, the epimerization of K5 derivatives rep-
resents a promising approach for the design of even more active
and specific anti-RSV compounds.
K5-OS(H) and K5-N,OS(H) are also revealed as exhibiting
more potent anti-RSV activity than heparin in viral yield reduc-
tion assays (Fig. 4) and in limiting RSV cell-to-cell spread (Fig. 5).
However, in the classic viral plaque assay and in the attachment
assays, K5-OS(H) and K5-N,OS(H) show IC50s that are compara-
ble to or only 2 to 5 times higher than that of heparin. It should be
mentioned, however, that these two assays somehow “favor” the
HSPG antagonist action of GAGs that are allowed to bind to the
virus before its administration to cells. Indeed, although these
assays are useful in their own right and are widely used for screen-
ing purposes, they do not resemble the in vivo situation, which is
characterized by the continuous release by infected cells of virions
that promptly interact with neighboring cells, often resulting in
direct cell-to-cell spread and syncytium formation.
Interestingly, we found that whenK5-OS(H) andK5-N,OS(H)
FIG 6 Antiviral assay with MA104 cells infected with human rotavirus.
MA104 cells were infected in the presence of K5 derivatives or heparin. Sixteen
hours postinfection, the cells were fixed and subjected to rotavirus-specific
immunostaining. The infected cells were counted, and the percent infection
was calculated by comparing treated and untreated wells. The results are
means and SEM from triplicates.
FIG7 Reduction of viral yield onEpiAirway tissue. Fifty thousandPFUand 10
M K5-N,OS(H) or K5-OS(H) were preincubated for 1 h at 4°C and subse-
quently added to the apical surface of the EpiAirway tissues. After 3 h of incu-
bation at 37°C, the medium was removed and the cultures were washed api-
cally with 100 l of medium. At 72 h postinfection, 100 l of medium was
added to the apical surface, and the tissues were allowed to equilibrate for 30
min at 37°C. The suspension was then collected and titrated on A549 cells. The
results are means and SEM from triplicates.
FIG 8 Reduction of RSV-infected cells in EpiAirway tissue by K5-N,OS(H)
and K5-OS(H). (A) Immunohistochemistry of control tissue; (B)RSV-in-
fected tissue (50,000 PFU); (C) RSV-infected tissue treated with 10 M K5-
N,OS(H); (D) RSV-infected tissue treated with 10 MK5-OS(H). Three days
postinfection, RSV-infected cells were identified using a RSV-specific mono-
clonal antibody (brown signal). The pictures shown are representative ofmany
analyzed sections, ranging from 5 to 12 per condition. Horizontal bars corre-
spond to 100 m.
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were assayed in the more stringent postinfection assay using
HEp-2 cells, they retained a long-lasting RSV-inhibitory capacity
comparable to that measured in the viral plaque assay, while hep-
arin was indicated to be less effective, remaining active for only for
short periods of time at concentrations that are 40 to 60 times
lower than those of the two K5 derivatives (Fig. 4). Accordingly,
K5-OS(H) and K5-N,OS(H) also presented significantly better
inhibitory profiles than heparin when assayed for their capacity to
inhibit RSV-induced syncytium formation (Fig. 5). K5-OS(H)
and K5-N,OS(H) have a backbone structure more similar to that
of HS than heparin, since they contain only GlcA, the presence of
which, along with their high sulfate contents, might make these
molecules more efficient than heparin in preventing electrostatic
interactions between theRSV glycoproteinsG and F andHSPGs at
the cell surface. Alternatively, the peculiar structure of K5 deriva-
tives may render these molecules more stable than heparin, thus
contributing to their persistent RSV-inhibitory activity.
In conclusion, not only are the active K5 derivatives able to
interfere with the virus adsorption process, but they also limit the
cell-to-cell spread of RSV in a dose-dependent manner at non-
toxic concentrations. These antiviral properties may be useful in
the clinical setting, where K5-OS(H) and K5-N,OS(H) might be
able to block both cell-to-cell spread and cell-free virus within the
extracellular space—the two predominant routes of dissemina-
tion for RSV in vivo (63, 64, 65, 66).
As mentioned above, heparin and heparan sulfates cannot be
used as anti-RSV drugs due to their anticoagulant activity and/or
aspecific activities. K5-OS(H) and K5-N,OS(H), on the other
hand, are endowed with a significantly lower anticoagulant activ-
ity (67). Moreover, since their structure is very similar to those of
natural heparan sulfates, they can bemetabolically recognized and
easily catabolizedwithout inducing toxicity, and they are expected
to be tolerated by the immune system. Accordingly, recent results
have shown that proinflammatory cytokines are not mobilized in
the presence of K5 derivatives (67) but rather can even exert an
anti-inflammatory effect (68).
Besides viral proteins (44), K5 derivatives are known to bind a
wide array of eukaryotic proteins (26), implying possible adverse
effects associated with their therapeutic administration. Relevant
to this point, this class of molecules can be suitably tailored to
produce countless compounds endowed with peculiar structural
features (degree of sulfation, disposition of sulfated groups, length
of GAG chain, and epimerization) (26) whose modulation im-
pacts their binding capacity (see the discussion above), thus sug-
gesting the possibility of producing selected K5 sulfated deriva-
tives with specific binding capacities and biological effects.
With regard to a potential administration of K5 derivatives for
the prevention or treatment of RSV infections, we assessed their
antiviral activities in human tracheal/bronchial histocultures
(EpiAirway). This model system avoids species extrapolation and
the use of animal models at the early preclinical phase of drug
development and provides a better simulation of the human re-
spiratory tract than the cell monolayers used in standard antiviral
assays. It carries the same cell type composition and polarity, mu-
cus-secreting function, andmucociliary movements as the airway
epithelium in vivo. Moreover, the HSPG composition and expres-
sion level in vivo are expected to be well duplicated in the EpiAir-
way tissue. In agreement with previous literature, we observed
that RSV infects the lumenal ciliated columnar airway epithelial
cells via the apical surfaces of the cultures, as shown in Fig. 8B (69).
Both the virus yield assays and the immunohistochemical analysis
of histological cross sections showed that K5-OS(H) and K5-
N,OS(H) exhibit clear antiviral activity in the EpiAirway tissue at
a dose of 10 M with no signs of cytotoxic effect, indicating that
this inhibitory strategy may well be effective in vivo. Studies to
assess the clinical potential of these inhibitors against RSV infec-
tions are ongoing in animal models.
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